Compared to the NGFR-cell population, N1/28z-engineered cells demonstrated a statistically significant superior expression of these markers (Fig. 3A - e.g.: 69.4% (MFI=38) of CD25-positive cells and 62.8% (MFI=48) of CD69-positive cells in co-cultures with K562 tumor targets). This evidence concerns the gene NGFR and neoplasm.